Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Inventory (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Inventory for 9 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory fell 36.78% year-over-year to $5.5 million, compared with a TTM value of $5.5 million through Dec 2025, down 36.78%, and an annual FY2025 reading of $5.5 million, down 36.78% over the prior year.
  • Inventory was $5.5 million for Q4 2025 at Puma Biotechnology, down from $9.5 million in the prior quarter.
  • Across five years, Inventory topped out at $9.5 million in Q3 2025 and bottomed at $2.7 million in Q3 2024.
  • Average Inventory over 5 years is $6.9 million, with a median of $7.2 million recorded in 2021.
  • The sharpest move saw Inventory crashed 52.93% in 2024, then soared 254.51% in 2025.
  • Year by year, Inventory stood at $7.1 million in 2021, then tumbled by 36.33% to $4.5 million in 2022, then surged by 56.43% to $7.1 million in 2023, then grew by 23.22% to $8.7 million in 2024, then crashed by 36.78% to $5.5 million in 2025.
  • Business Quant data shows Inventory for PBYI at $5.5 million in Q4 2025, $9.5 million in Q3 2025, and $8.6 million in Q2 2025.